



Final Appraisal Recommendation

Advice number: 1622 – September 2022

Rituximab (MabThera®) 100 mg and 500 mg concentrate for solution for infusion

Roche Products Ltd

Recommendation of the All Wales Medicines Strategy Group

Rituximab (MabThera®) is recommended as an option for use within NHS Wales for the treatment of patients with moderate to severe pemphigus vulgaris.

Rituximab should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.

Additional note(s):

- Existing health technology assessment (HTA) advice for the 'reference' medicine, published by AWMSG or the National Institute for Health and Care Excellence (NICE), will automatically apply for biosimilar medicines licensed for the same indication and in the same population as the 'reference' medicine.
- Rituximab should be prescribed on the basis of lowest acquisition cost.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3192), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review after three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 1622:

Rituximab (MabThera®) 100 mg and 500 mg concentrate for solution for infusion

